Navigation Links
inVentiv Health to Present at the 2008 UBS Global Healthcare Services Conference
Date:2/4/2008

ss release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.


'/>"/>
SOURCE inVentiv Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
10. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
11. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... Market Study on Membrane Technology in Pharmaceutical, Biopharma and ... Witness Highest Growth by 2019" the global membrane technology market for ... 7,029.9 million in 2014 and is expected to grow ... to reach an estimated value of USD 10,886.0 million ...
(Date:9/2/2014)... , Sept. 2, 2014 Orexigen Therapeutics, ... the U.S. Patent and Trademark Office (PTO) has issued ... being evaluated for weight loss. NB32 is a fixed-dose ... U.S. Patent No. 8,815,889 claims methods for ... bupropion. The patent expires in 2024. If NB32 is ...
(Date:9/2/2014)... NC (PRWEB) September 02, 2014 ... of its 11th clinical research site: PMG Research of ... ownership and operation of the clinical research department at ... expanding PMG’s presence in eastern North Carolina. This new ... For the patients in Rocky Mount and the surrounding ...
(Date:9/1/2014)... The global oligonucleotide synthesis market is expected to ... in 2014, growing at a CAGR of 9.8% ... market is categorized on the basis of products ... synthesized oligonucleotides segment is expected to register the ... during the forecast period, owing to an increasing ...
Breaking Biology Technology:Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... Inc. (NYSE Amex: CUR ) announced it ... develop its human neural stem cell technology for the ... "Research to Treat Cancerous Brain Tumors with Neural Stem ... Investigator John Zhang, MD, PhD, Professor of Neurosurgery, Loma ...
... that attacks the small intestines of humans and animals ... can fight disease and aid in military operations. ... engineering, at the University of Tennessee, Knoxville, and his ... attachment of the microorganism Giardia. Giardia causes one of ...
... Informex , the leading meeting place for buyers ... introduction of a new conference, ,Business Strategies for ... to be hosted October 5-6th, 2011 in Boston, ... topics regarding the future of pharma, sourcing strategies ...
Cached Biology Technology:Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 3UT professor's pathogen research inspires robotics design for medicine and military 2New Conference Offers Solutions for Success in the Growing Biologics Market 2New Conference Offers Solutions for Success in the Growing Biologics Market 3
(Date:9/2/2014)... suggests that professional baseball pitchers with poor core stability are ... single season because of injury than are pitchers who have ... , In the study, 347 pitchers were assessed for lumbopelvic ... pelvis as they raised a leg to step up were ... 30 days cumulative, not consecutive during the season ...
(Date:9/2/2014)... If you think losing weight is enough to prevent Type ... report in September 2014 issue of The FASEB ... overweight to develop Type 2 diabetes. This study compared genetically ... a fast-food meal, the circulating metabolites, including those related to ... same levels. These findings suggest that the onset of ...
(Date:9/2/2014)... (September 2, 2014) In the battle between our ... unknown ally in bacteria-killing viruses known as phages. In ... Hospital, Partners In Health, Haiti,s National Public Health Laboratory, ... to give up their virulence in order to survive. ... found that cholera,s mutational escape from phage predation ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3What you eat and not just the number of calories, is a significant factor in diabetes risk 2War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3
... Long touted as an energy-saving alternative for home ... to be even more efficient, as well as dimmable, ... by householders as a longer-lasting, energy efficient alternative to ... the power and last 1,000 times longer than incandescent ...
... and her colleagues have identified a specific DNA change ... in some people. It provides a potential mechanism that ... consistent with the growing trend of personalized medicine. ... issue of the American Journal of Psychiatry ...
... used as live bait for freshwater fishing. With ... channel catfish and other freshwater fishes. They may ... in bait shops in Arizona, Colorado and New Mexico ... a chytrid fungus called Batrachochytrium dendrobatidis (Bd). "These ...
Cached Biology News:Queen's researchers shine light on compact fluorescent bulb problems 2Altered gene can increase risk of schizophrenia 2Altered gene can increase risk of schizophrenia 3Spring fishing season arrives... and with it, amphibian diseases 2Spring fishing season arrives... and with it, amphibian diseases 3
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
... CGH Genomic Labeling Systems are a high-performance ... genomic DNA samples for array-based Comparative Genomic ... direct labeling formats, the BioPrime Plus Array ... solution to your genomic labeling needs. ...
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
Biology Products: